These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20872599)

  • 1. Thrombovascular events in systemic lupus erythematosus: comment on the article by Jung et al.
    Wallace DJ
    Arthritis Rheum; 2010 Sep; 62(9):2824; author reply 2824-5. PubMed ID: 20872599
    [No Abstract]   [Full Text] [Related]  

  • 2. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus.
    Jung H; Bobba R; Su J; Shariati-Sarabi Z; Gladman DD; Urowitz M; Lou W; Fortin PR
    Arthritis Rheum; 2010 Mar; 62(3):863-8. PubMed ID: 20131232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE.
    Wallace DJ; Linker-Israeli M; Metzger AL; Stecher VJ
    Lupus; 1993 Feb; 2 Suppl 1():S13-5. PubMed ID: 8485565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxychloroquine blood assay as a marker of nonadherence in patients with systemic lupus erythematosus: comment on the article by Koneru et al.
    Costedoat-Chalumeau N; Amoura Z; Marra D; Piette JC
    Arthritis Rheum; 2008 Jan; 59(1):153; author reply 153-4. PubMed ID: 18163410
    [No Abstract]   [Full Text] [Related]  

  • 5. Hydroxychloroquine: the cornerstone of lupus therapy.
    Ruiz-Irastorza G; Khamashta MA
    Lupus; 2008 Apr; 17(4):271-3. PubMed ID: 18413405
    [No Abstract]   [Full Text] [Related]  

  • 6. [Blepharitis--rare in systemic lupus erythematosus].
    Gyl F; Anna-Adrien C; Oanţă A; Irimie M; Edit FJ
    Oftalmologia; 2008; 52(2):81-3. PubMed ID: 19065920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis.
    Petri M
    Lupus; 1996 Jun; 5 Suppl 1():S16-22. PubMed ID: 8803905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombosis in systemic lupus erythematosus: risk and protection.
    Burgos PI; Alarcón GS
    Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1541-9. PubMed ID: 19954316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients.
    Petri M
    Curr Rheumatol Rep; 2011 Feb; 13(1):77-80. PubMed ID: 20978875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimalarial drug-induced aquagenic-type pruritus in patients with lupus.
    Jiménez-Alonso J; Tercedor J; Jáimez L; García-Lora E
    Arthritis Rheum; 1998 Apr; 41(4):744-5. PubMed ID: 9550488
    [No Abstract]   [Full Text] [Related]  

  • 11. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus.
    Parke A; West B
    J Rheumatol; 1996 Oct; 23(10):1715-8. PubMed ID: 8895146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of hydroxychloroquine in lupus pregnancy: the British experience.
    Khamashta MA; Buchanan NM; Hughes GR
    Lupus; 1996 Jun; 5 Suppl 1():S65-6. PubMed ID: 8803914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimalarial drugs, systemic lupus erythematosus and pregnancy.
    Parke AL
    J Rheumatol; 1988 Apr; 15(4):607-10. PubMed ID: 3397970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimalarial agents and lupus.
    Wallace DJ
    Rheum Dis Clin North Am; 1994 Feb; 20(1):243-63. PubMed ID: 8153401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corticosteroids in preventing severe lupus flares: do all patients have the same risk? Comment on the article by Tseng et al.
    Callejas-Rubio JL; Rios-Fernández R; Tomás-Jiménez C; Ortego-Centeno N
    Arthritis Rheum; 2007 Jun; 56(6):2098-9; author reply 2099. PubMed ID: 17530655
    [No Abstract]   [Full Text] [Related]  

  • 16. Antimalarials--the 'real' advance in lupus.
    Wallace DJ
    Lupus; 2001; 10(6):385-7. PubMed ID: 11434570
    [No Abstract]   [Full Text] [Related]  

  • 17. Antimalarial therapy in SLE.
    Lanham JG; Hughes GR
    Clin Rheum Dis; 1982 Apr; 8(1):279-98. PubMed ID: 6749400
    [No Abstract]   [Full Text] [Related]  

  • 18. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
    Wang C; Fortin PR; Li Y; Panaritis T; Gans M; Esdaile JM
    J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Systemic lupus erythematosus therapy. Antimalarials in inflammatory diseases].
    Yebra-Bango M; Tutor-Ureta P
    Rev Clin Esp; 2004 Nov; 204(11):565-6. PubMed ID: 15511401
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.
    Tektonidou MG; Laskari K; Panagiotakos DB; Moutsopoulos HM
    Arthritis Rheum; 2009 Jan; 61(1):29-36. PubMed ID: 19116963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.